RXi Pharmaceuticals (RXII) Shares Gap Up to $0.44

Share on StockTwits

RXi Pharmaceuticals Corp (NASDAQ:RXII)’s share price gapped up before the market opened on Thursday . The stock had previously closed at $0.45, but opened at $0.44. RXi Pharmaceuticals shares last traded at $0.47, with a volume of 269354 shares changing hands.

RXII has been the topic of several recent research reports. HC Wainwright reiterated a “buy” rating on shares of RXi Pharmaceuticals in a research report on Monday, October 15th. ValuEngine upgraded RXi Pharmaceuticals from a “hold” rating to a “buy” rating in a research report on Thursday, November 1st.

The stock has a market cap of $1.93 million, a P/E ratio of -0.10 and a beta of 2.07.

RXi Pharmaceuticals (NASDAQ:RXII) last posted its quarterly earnings results on Tuesday, August 14th. The biotechnology company reported ($0.46) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.62) by $0.16. The company had revenue of $0.06 million for the quarter, compared to the consensus estimate of $0.02 million. As a group, equities analysts forecast that RXi Pharmaceuticals Corp will post -1.55 earnings per share for the current fiscal year.

A hedge fund recently bought a new stake in RXi Pharmaceuticals stock. SG Americas Securities LLC purchased a new position in shares of RXi Pharmaceuticals Corp (NASDAQ:RXII) during the 2nd quarter, according to its most recent 13F filing with the SEC. The firm purchased 118,387 shares of the biotechnology company’s stock, valued at approximately $228,000. SG Americas Securities LLC owned about 2.78% of RXi Pharmaceuticals at the end of the most recent reporting period. 8.87% of the stock is owned by hedge funds and other institutional investors.

ILLEGAL ACTIVITY NOTICE: This article was first published by Week Herald and is owned by of Week Herald. If you are reading this article on another domain, it was copied illegally and reposted in violation of United States and international copyright & trademark laws. The correct version of this article can be read at https://weekherald.com/2018/11/10/rxi-pharmaceuticals-rxii-shares-gap-up-to-0-44.html.

About RXi Pharmaceuticals (NASDAQ:RXII)

RXi Pharmaceuticals Corporation, a biotechnology company, focuses on discovering and developing immuno-oncology therapeutics to treat cancer. The company's lead product candidate is RXI-109, an sd-rxRNA that reduces the expression of connective tissue growth factor, a critical regulator of several biological pathways involved in fibrosis, including scar formation in the skin and eye.

Read More: Discount Rate

Receive News & Ratings for RXi Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for RXi Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply